Radiosurgery Dose Reduction for Brain Metastases on Immunotherapy (RADREMI): A Prospective Pilot Study

Study Overview

The purpose of this study is to assess the efficacy and safety of a lower dose than is usually given of stereotactic radiosurgery (i.e. Gamma Knife or Linear Accelerator) for brain metastases patients receiving immunotherapy.

Study Description

Researchers will collect a blood sample and information from participants' medical record. Participants will receive stereotactic radiosurgery (SRS) to a dose according to the size of their metastatic brain disease. Participants will undergo normal clinical (examinations) and radiographic (brain MRI with contrast) follow-up one month after SRS and every three months after SRS for a full year.

None of the procedures participants undergo will be experimental; all are standard of care. However, the lower dose of stereotactic radiosurgery they will receive is not standard of care.

  • IRB Number: 1906336263
  • Research Study Identifier: 1906336263

Recruitment Status


Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Volunteer Sign up

Volunteer Registry

Create your profile and be matched to research opportunities

Register Now!

Contact Us

If you need help finding a study or have any questions, please contact us at or by phone at (888) 264-0005.